JP5389662B2 - 高濃度のグアニン・モノマーを含有するオリゴヌクレオチド - Google Patents

高濃度のグアニン・モノマーを含有するオリゴヌクレオチド Download PDF

Info

Publication number
JP5389662B2
JP5389662B2 JP2009541546A JP2009541546A JP5389662B2 JP 5389662 B2 JP5389662 B2 JP 5389662B2 JP 2009541546 A JP2009541546 A JP 2009541546A JP 2009541546 A JP2009541546 A JP 2009541546A JP 5389662 B2 JP5389662 B2 JP 5389662B2
Authority
JP
Japan
Prior art keywords
oligonucleotide
solvent
seq
coupling
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009541546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512169A5 (https=
JP2010512169A (ja
Inventor
ブライアン， スティーヴン スプロート，
Original Assignee
サイトス バイオテクノロジー アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイトス バイオテクノロジー アーゲー filed Critical サイトス バイオテクノロジー アーゲー
Publication of JP2010512169A publication Critical patent/JP2010512169A/ja
Publication of JP2010512169A5 publication Critical patent/JP2010512169A5/ja
Application granted granted Critical
Publication of JP5389662B2 publication Critical patent/JP5389662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009541546A 2006-12-12 2007-12-12 高濃度のグアニン・モノマーを含有するオリゴヌクレオチド Active JP5389662B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86958806P 2006-12-12 2006-12-12
US60/869,588 2006-12-12
PCT/US2007/087183 WO2008073960A2 (en) 2006-12-12 2007-12-12 Oligonucleotides containing high concentrations of guanine monomers

Publications (3)

Publication Number Publication Date
JP2010512169A JP2010512169A (ja) 2010-04-22
JP2010512169A5 JP2010512169A5 (https=) 2011-03-24
JP5389662B2 true JP5389662B2 (ja) 2014-01-15

Family

ID=39456527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009541546A Active JP5389662B2 (ja) 2006-12-12 2007-12-12 高濃度のグアニン・モノマーを含有するオリゴヌクレオチド

Country Status (7)

Country Link
US (3) US8586728B2 (https=)
EP (1) EP2125854B1 (https=)
JP (1) JP5389662B2 (https=)
CN (1) CN101611048B (https=)
AU (1) AU2007333147B2 (https=)
CA (1) CA2671873C (https=)
WO (1) WO2008073960A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008063490B4 (de) * 2008-12-17 2023-06-15 Merck Patent Gmbh Organische Elektrolumineszenzvorrichtung und Verfahren zum Einstellen des Farbortes einer weiß emittierenden Elektrolumineszenzvorrichtung
WO2012059510A1 (en) 2010-11-02 2012-05-10 Girindus America, Inc. Back pressure control during solid-phase synthesis on polymeric supports
US10040048B1 (en) 2014-09-25 2018-08-07 Synthego Corporation Automated modular system and method for production of biopolymers
PL3240801T3 (pl) 2014-12-31 2021-06-14 Checkmate Pharmaceuticals, Inc. Skojarzona immunoterapia nowotworów
WO2017005818A1 (en) * 2015-07-08 2017-01-12 Kuros Biosciences Ag Guanine-rich oligonucleotides
WO2017111137A1 (ja) 2015-12-22 2017-06-29 味の素株式会社 オリゴヌクレオチドの製造方法
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
US20190076814A1 (en) 2017-09-11 2019-03-14 Synthego Corporation Biopolymer synthesis system and method
CN111246936B (zh) * 2017-10-25 2022-05-03 深圳华大生命科学研究院 用于核酸合成的微流控芯片
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
EP3850096A1 (en) * 2018-09-11 2021-07-21 Amgen Inc. Purification methods for guanine-rich oligonucleotides
CA3117823A1 (en) * 2018-10-30 2020-05-07 Toray Industries, Inc. Inhibitor of non-specific binding of nucleic acid, hybridization reagent and nucleic acid hybridization method
WO2020093322A1 (zh) * 2018-11-08 2020-05-14 深圳华大生命科学研究院 一种微流控芯片及其制备方法和dna合成方法
EP4047004B1 (en) * 2019-10-18 2024-03-06 FUJIFILM Wako Pure Chemical Corporation Phosphoramidite activator
US20230322842A1 (en) * 2020-04-14 2023-10-12 Sumitomo Chemical Company, Limited Composition containing nucleic acid oligomer
CN114425443B (zh) * 2020-10-29 2025-10-31 江苏金斯瑞生物科技有限公司 一种寡核苷酸合成催化剂
GB202114688D0 (en) 2021-10-14 2021-12-01 Exactmer Ltd Solution phase polymer synthesis
GB202414228D0 (en) 2024-09-27 2024-11-13 Exactmer Ltd Solvent recycling in a liquid-phase process for preparing a defined monomoer sequence polymer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500817A (ja) * 1983-06-01 1985-05-30 ベツクマン・インストルメンツ・インコ−ポレ−テツド ヌクレオシド・ホスホルアミダイト中間体の製造方法
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
WO1998049195A1 (en) 1997-04-29 1998-11-05 Universiteit Utrecht Corona virus-like particles as tools for vaccination and therapy
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
US6171591B1 (en) 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
US6541438B1 (en) * 1998-05-01 2003-04-01 The Procter & Gamble Company Laundry detergent and/or fabric care compositions comprising a modified cellulase
DE69929232T2 (de) * 1998-10-21 2006-08-31 The United States Government As Represented By The Department Of Health And Human Services Virusähnliche partikel zur induktion von autoantikörpern
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
WO2000046365A1 (en) 1999-02-02 2000-08-10 Biocache Pharmaceuticals, Inc. Advanced antigen presentation platform
EP1156781B1 (en) 1999-02-26 2005-06-08 Chiron Corporation Microemulsions with adsorbed macromolecules and microparticles
NZ517929A (en) * 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
AU783118B2 (en) 1999-09-27 2005-09-29 Coley Pharmaceutical Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
PT1221968E (pt) 1999-10-13 2010-04-16 Novartis Vaccines & Diagnostic Processo de obtenção de respostas imunes celulares de proteínas
EP1233783B9 (en) 1999-11-24 2006-03-15 Chiron Corporation Hbv/hcv virus-like particle
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
JP2003523398A (ja) 2000-02-24 2003-08-05 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 樹状細胞のインビボ活性化によるアジュバント治療
WO2002053141A2 (en) 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
CA2492823A1 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
US7524950B2 (en) * 2001-10-31 2009-04-28 Agilent Technologies, Inc. Uses of cationic salts for polynucleotide synthesis
BR0311995A (pt) * 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
AU2004224761A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
RU2375076C2 (ru) 2003-07-10 2009-12-10 Цитос Биотехнологи Аг Укомплектованные вирусоподобные частицы
US20060182793A1 (en) * 2003-07-22 2006-08-17 Cytos Biotechnology Ag Cpg-packaged liposomes
JP4628686B2 (ja) * 2004-02-25 2011-02-09 独立行政法人科学技術振興機構 ホスホロアミダイトを含む３’末端ヌクレオシドユニット
CN101076546B (zh) * 2004-09-02 2011-10-26 Isis药物公司 用于低聚物合成的聚合珠
MX2007003171A (es) * 2004-09-21 2007-05-23 Cytos Biotechnology Ag Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico.
CA2636139A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity

Also Published As

Publication number Publication date
CN101611048B (zh) 2012-11-07
EP2125854A2 (en) 2009-12-02
US8586728B2 (en) 2013-11-19
US20160145293A1 (en) 2016-05-26
AU2007333147A1 (en) 2008-06-19
WO2008073960A3 (en) 2008-08-07
AU2007333147B2 (en) 2013-12-19
JP2010512169A (ja) 2010-04-22
US9914746B2 (en) 2018-03-13
CN101611048A (zh) 2009-12-23
CA2671873C (en) 2018-10-09
CA2671873A1 (en) 2008-06-19
US20140200338A1 (en) 2014-07-17
EP2125854B1 (en) 2016-10-26
WO2008073960A2 (en) 2008-06-19
US20080139797A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
JP5389662B2 (ja) 高濃度のグアニン・モノマーを含有するオリゴヌクレオチド
JP7377228B2 (ja) グアニンリッチオリゴヌクレオチド
JP2010248084A (ja) 新規洗浄溶媒を用いるオリゴヌクレオチド合成法
CN102076703B (zh) 用于制造寡核苷酸的方法
KR20230145318A (ko) 올리고뉴클레오타이드의 탈트리틸화 방법
WO2000012524A1 (en) Purification of oligomers using dual-end selection
KR102709587B1 (ko) 이메텔스타트를 제조하기 위한 향상된 공정
CA2424716A1 (en) Process for producing multiple oligonucleotides on a solid support
US20030195351A1 (en) Methods for the integrated synthesis and purification of oligonucleotides
AU2013204442A1 (en) Oligonucleotides Containing High Concentrations of Guanine Monomers
JP2000342265A (ja) オリゴヌクレオチド類の精製方法
ES2741025T3 (es) Oligonucleótidos ricos en guanina
KR20260049191A (ko) 올리고뉴클레오티드를 제조하는 방법
Xu et al. Site-specific introduction of functional groups onto bases in synthetic oligonucleotides for biological applications
HK40031465A (en) Improved process for preparing imetelstat
HK40031465B (en) Improved process for preparing imetelstat

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20101210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130524

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131009

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5389662

Country of ref document: JP

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250